Skip to content
MedicalCoreCoding

Try a topic like assisted living, critical care or a code like 99214.

National Colony, Aurangabad, 431001 · Mon - Fri: 9am - 5pm

Report #8 · Office & outpatient

Gastroparesis: ongoing nausea and vomiting

4 questionsCOPADataRiskMDM
Jump to the questions

Clinical note · #8

Office & outpatient

Provider: Dr. Last Name, First Name, MD

Date: 10/26/2023

Patient Information

Name: John Johnson

Date of Birth: 08/18/1955

Sex: Male

Medical Record Number: 765432109

Chief Complaint

Mr. Johnson's chief complaints include ongoing nausea and vomiting attributed to gastroparesis related to his diabetes. He experiences unpredictable episodes of vomiting after eating without specific food triggers. Zofran has been effective in providing relief when taken. In addition, he reports vertigo triggered by head movement and positional changes.

Medical History:

Mr. Johnson has a history of diabetes, which is contributing to his gastroparesis. He has experienced recurrent nausea and vomiting associated with this condition.

Objective Findings:

Upon examination:

  • Mr. Johnson is lying flat in bed, watching television, and is pleasant and conversational.

  • He demonstrates good recall and communication skills, although he speaks quietly.

  • No abnormalities found during head, eyes, ears, nose, and throat (HEENT) examination.

  • Clear lung sounds.

  • Cardiac examination reveals a regular rate and rhythm.

  • Abdomen is soft, non-tender, with normal bowel sounds and no distension.

Assessment and Plan

1. Gastroparesis:

  • Initiate a trial of Zofran (ondansetron) 4 mg orally three times a day (TID) for 10 days to manage nausea and vomiting due to gastroparesis.
  • Monitor for signs of improvement in symptoms.

2. Benign Paroxysmal Positional Vertigo:

  • Consider a trial of meclizine 12.5 mg orally three times a day (TID) for 10 days to address vertigo triggered by head movement and positional changes.
  • Monitor for improvement in vertigo symptoms.

3. Follow-up:

  • Schedule a follow-up appointment in 10 days to assess the patient's response to the prescribed treatments.

Signed by the provider · 10/26/2023